WASHINGTON TRUST Co Sells 402 Shares of Novo Nordisk A/S (NYSE:NVO)

WASHINGTON TRUST Co trimmed its position in Novo Nordisk A/S (NYSE:NVO) by 44.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 503 shares of the company’s stock after selling 402 shares during the period. WASHINGTON TRUST Co’s holdings in Novo Nordisk A/S were worth $43,000 as of its most recent filing with the SEC.

Several other large investors have also bought and sold shares of NVO. International Assets Investment Management LLC raised its position in Novo Nordisk A/S by 10,608.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after purchasing an additional 1,796,635 shares during the last quarter. Mediolanum International Funds Ltd bought a new position in Novo Nordisk A/S during the 3rd quarter worth $98,765,000. DAVENPORT & Co LLC raised its position in Novo Nordisk A/S by 75.1% during the 4th quarter. DAVENPORT & Co LLC now owns 1,052,712 shares of the company’s stock worth $90,477,000 after purchasing an additional 451,641 shares during the last quarter. Wellington Management Group LLP bought a new position in Novo Nordisk A/S during the 3rd quarter worth $42,017,000. Finally, World Investment Advisors LLC raised its position in Novo Nordisk A/S by 2,655.9% during the 3rd quarter. World Investment Advisors LLC now owns 280,409 shares of the company’s stock worth $33,388,000 after purchasing an additional 270,234 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $77.94 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.75. The stock has a 50-day moving average of $88.65 and a 200-day moving average of $109.83. The company has a market cap of $349.75 billion, a PE ratio of 23.69, a P/E/G ratio of 0.96 and a beta of 0.45. Novo Nordisk A/S has a one year low of $77.82 and a one year high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, equities research analysts predict that Novo Nordisk A/S will post 3.86 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be paid a $0.7874 dividend. The ex-dividend date is Monday, March 31st. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 21.88%.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Morgan Stanley assumed coverage on Novo Nordisk A/S in a research report on Wednesday. They set an “equal weight” rating for the company. BMO Capital Markets decreased their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Finally, UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.